Calculation of operating expenses for conventional transarterial chemoembolization in an academic medical center: a step toward defining the value of transarterial chemoembolization
- PMID: 24462006
- DOI: 10.1016/j.jvir.2013.10.023
Calculation of operating expenses for conventional transarterial chemoembolization in an academic medical center: a step toward defining the value of transarterial chemoembolization
Abstract
Purpose: To determine the "real cost" of conventional transarterial chemoembolization in the treatment of patients with unresectable hepatocellular carcinoma (HCC).
Materials and methods: Comprehensive cost data for performance of conventional transarterial chemoembolization were calculated from a retrospective review of records of 50 consecutive outpatient transarterial chemoembolization procedures in 36 patients with HCC. Costs included labor, equipment, facility acquisition and maintenance, overhead, and administrative costs in a single academic medical center. Hourly rate operational costs for the angiography suite and recovery area were calculated, to which the consumable supply costs were added. Conventional transarterial chemoembolization was defined as selective intrahepatic administration of chemotherapeutic agents (doxorubicin and mitomycin C) emulsified in ethiodized oil (Lipiodol).
Results: The hourly rate to operate an angiography suite at the institution was calculated to be $539/h. Recovery time was calculated at $108/h. Median overall cost of conventional transarterial chemoembolization was $3,269 (range, $2,223-$5,654). This overall cost comprised median room and personnel costs of $763 (range, $404-$1,797), consumable costs of $1,886 (range, $1,134-$4,126), and recovery costs of $378 (range, $162-$864).
Conclusions: The largest contribution (62%) to the real cost of outpatient transarterial chemoembolization comes from the expendable equipment used in the procedure. The angiography suite and personnel costs constitute 25% of the total, and recovery costs constitute 13%. This finding is a change from previous reports in which angiography suite operation was the greatest contributor to cost. Understanding real cost is an essential step in determining the value of the procedure.
Published by Elsevier Inc.
Comment in
-
The importance of the value proposition for IR.J Vasc Interv Radiol. 2014 Apr;25(4):575. doi: 10.1016/j.jvir.2013.10.031. J Vasc Interv Radiol. 2014. PMID: 24674215 No abstract available.
Similar articles
-
Cost Accounting as a Tool for Increasing Cost Transparency in Selective Hepatic Transarterial Chemoembolization.J Vasc Interv Radiol. 2015 Dec;26(12):1820-6.e1. doi: 10.1016/j.jvir.2015.09.004. Epub 2015 Oct 27. J Vasc Interv Radiol. 2015. PMID: 26521766
-
Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma.J Vasc Interv Radiol. 2014 Jul;25(7):1075-84. doi: 10.1016/j.jvir.2014.04.014. Epub 2014 May 24. J Vasc Interv Radiol. 2014. PMID: 24861664 Review.
-
The importance of the value proposition for IR.J Vasc Interv Radiol. 2014 Apr;25(4):575. doi: 10.1016/j.jvir.2013.10.031. J Vasc Interv Radiol. 2014. PMID: 24674215 No abstract available.
-
Interventional radiologic treatment of hepatocellular carcinoma-a cost analysis from the payer perspective.J Vasc Interv Radiol. 2012 Mar;23(3):306-14. doi: 10.1016/j.jvir.2011.11.016. Epub 2012 Jan 25. J Vasc Interv Radiol. 2012. PMID: 22277271
-
90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness.J Comp Eff Res. 2013 Jul;2(4):435-44. doi: 10.2217/cer.13.37. J Comp Eff Res. 2013. PMID: 24236684 Review.
Cited by
-
Review of preoperative transarterial chemoembolization for resectable hepatocellular carcinoma.World J Hepatol. 2015 Jan 27;7(1):40-3. doi: 10.4254/wjh.v7.i1.40. World J Hepatol. 2015. PMID: 25624995 Free PMC article. Review.
-
Economic analysis of n-butyl cyanoacrylate compared with ethylene vinyl alcohol copolymer liquid embolic embolization of brain arteriovenous malformations (bAVMs) from a US hospital perspective.Interv Neuroradiol. 2023 Aug;29(4):434-441. doi: 10.1177/15910199221089766. Epub 2022 Apr 21. Interv Neuroradiol. 2023. PMID: 35450458 Free PMC article.
-
A Cross-Sectional Survey of Interventional Radiologists and Vascular Surgeons Regarding the Cost and Reimbursement of Common Devices and Procedures.J Vasc Interv Radiol. 2016 Feb;27(2):210-8. doi: 10.1016/j.jvir.2015.10.024. Epub 2015 Dec 17. J Vasc Interv Radiol. 2016. PMID: 26706189 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical